CR Pharmaceutical Becomes Constituent of MSCI China Index Once Again
Retrieved on:
Sunday, November 13, 2022
Growth, Pharmacy, DTP, Hospital, R, Methodology, QFII, QDII, Health, Research, Quality of life, Fine chemical
HONG KONG, Nov 14, 2022 - (ACN Newswire) - China Resources Pharmaceutical Group Limited ("CR Pharmaceutical" or the "Group") (stock code: 3320) has announced that the Group will once again be included as a constituent stock of the MSCI China Index, which will become effective after the market close on 30 November 2022.
Key Points:
- HONG KONG, Nov 14, 2022 - (ACN Newswire) - China Resources Pharmaceutical Group Limited ("CR Pharmaceutical" or the "Group") (stock code: 3320) has announced that the Group will once again be included as a constituent stock of the MSCI China Index, which will become effective after the market close on 30 November 2022.
- The inclusion of the Group in the MSCI China Index reaffirms the market's recognition of the Group's business development.
- China Resources Pharmaceutical Group Limited ("CR Pharm", stock code: 3320) is a leading integrated pharmaceutical company in China.
- CR Pharm is one of the largest pharmaceutical enterprises (manufacturing 600 products), the largest manufacturer of over-the-counter drugs and the third largest distributor of pharmaceutical products in China.